Understand · Treat · Recover

Rare Ovarian Cancer Subtypes

Uncommon tumours deserve specialist pathology and a treatment plan built around their biology.

This guide is educational and does not replace individual medical assessment. Do not start, stop or change treatment without the treating team. Cancer Aware supports patients and families worldwide. Drug approvals, availability, affordability and care pathways vary by country.

Chapter 15 of 20

Low-grade serous cancer

Low-grade serous cancer is usually less responsive to conventional chemotherapy than high-grade serous cancer. Surgery, hormone therapy such as an aromatase inhibitor, and selected targeted agents can be important. Trametinib is an evidence-supported option in recurrent disease in appropriate settings. In the US, avutometinib with defactinib received accelerated approval in 2025 for KRAS-mutated recurrent low-grade serous cancer after prior systemic therapy; ongoing evidence and local access should be discussed.

Germ-cell tumours

These often affect younger patients. Surgery preserving the uterus and an unaffected ovary may be possible even when chemotherapy is needed. Many malignant germ-cell tumours are highly treatment-sensitive, including some advanced cases. BEP—bleomycin, etoposide and cisplatin—is one established regimen, but some selected stage I cases can be observed. AFP, beta-hCG and LDH are used according to subtype.

Stromal, clear-cell and mucinous tumours

Granulosa-cell tumours can produce hormones and may relapse late; long follow-up is important. Endometrial assessment may be needed when abnormal bleeding or oestrogen effects are present. Clear-cell and mucinous carcinomas differ from high-grade serous cancer; advanced disease may warrant molecular assessment or trials. Confirm a primary ovarian origin before treating a mucinous mass as ovarian cancer.

Borderline tumours

These are not equivalent to ordinary invasive carcinoma. Surgery and surveillance are central; chemotherapy is not routine after completely resected borderline disease. Fertility-sparing approaches can be possible, but recurrence risk, implants and any invasive component must be assessed by experienced specialists.

Key takeaway

Do not apply the high-grade serous treatment template to every ovarian tumour.

Common questions

Is a rare tumour necessarily harder to cure?

No. Some rare germ-cell cancers have excellent treatment sensitivity.

Is low-grade serous cancer treated exactly like high-grade serous?

No. Its biology and treatment priorities differ.

Can hormone tablets treat ovarian tumours?

Yes, in selected hormone-sensitive subtypes.

Do granulosa-cell tumours need long follow-up?

Yes. Recurrence can occur many years later.

Does a borderline diagnosis always need chemotherapy?

No. Surgery and surveillance are usually central; specialist pathology matters.

Sources and further reading